FDA rejected Capricor’s BLA for Deramiocel due to insufficient evidence, requesting more clinical data to support approval for Duchenne therapy.
Capricor’s Lead Duchenne Therapy Hits FDA Regulatory Roadblock
Where Today's News Shapes Tomorrow
March 4, 2026
Headlines
